Galsky MD - Search Results

1

The role of GATA2 in lethal prostate cancer aggressiveness.

Rodriguez-Bravo V, Carceles-Cordon M, Hoshida Y, Cordon-Cardo C, Galsky MD, Domingo-Domenech J. Rodriguez-Bravo V, et al. Among authors: galsky md. Nat Rev Urol. 2017 Jan;14(1):38-48. doi: 10.1038/nrurol.2016.225. Epub 2016 Nov 22. Nat Rev Urol. 2017. PMID: 27872477 Free PMC article. Review.

2

Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.

Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J, Ross RW. Oh WK, et al. Among authors: galsky md. Urology. 2011 Sep;78(3):626-30. doi: 10.1016/j.urology.2011.04.041. Epub 2011 Jul 18. Urology. 2011. PMID: 21762967 Free PMC article. Clinical Trial.

3

Overcoming castration resistance in prostate cancer.

Tsao CK, Small AC, Galsky MD, Oh WK. Tsao CK, et al. Among authors: galsky md. Curr Opin Urol. 2012 May;22(3):167-74. doi: 10.1097/MOU.0b013e3283523b8b. Curr Opin Urol. 2012. PMID: 22472508 Review.

4

The emerging role of circulating tumor cell detection in genitourinary cancer.

Small AC, Gong Y, Oh WK, Hall SJ, van Rijn CJ, Galsky MD. Small AC, et al. Among authors: galsky md. J Urol. 2012 Jul;188(1):21-6. doi: 10.1016/j.juro.2012.02.2558. Epub 2012 May 12. J Urol. 2012. PMID: 22578722 Review.

5

Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).

Tsao CK, Galsky MD, Small AC, Yee T, Oh WK. Tsao CK, et al. Among authors: galsky md. BJU Int. 2012 Dec;110(11):1580-8. doi: 10.1111/j.1464-410X.2012.11445.x. Epub 2012 Sep 18. BJU Int. 2012. PMID: 22985411 Review.

6

Advances in the management of muscle-invasive bladder cancer through risk prediction, risk communication, and novel treatment approaches.

Galsky MD, Domingo-Domenech J. Galsky MD, et al. Clin Adv Hematol Oncol. 2013 Feb;11(2):86-92. Clin Adv Hematol Oncol. 2013. PMID: 23598909 Review.

7

Targeting cancer stem cells to suppress acquired chemotherapy resistance.

Vidal SJ, Rodriguez-Bravo V, Galsky M, Cordon-Cardo C, Domingo-Domenech J. Vidal SJ, et al. Oncogene. 2014 Sep 4;33(36):4451-63. doi: 10.1038/onc.2013.411. Epub 2013 Oct 7. Oncogene. 2014. PMID: 24096485 Review.

8

Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer.

Tsao CK, Galsky MD, Oh WK. Tsao CK, et al. Among authors: galsky md. Eur Urol. 2014 Aug;66(2):184-5. doi: 10.1016/j.eururo.2013.12.061. Epub 2014 Jan 7. Eur Urol. 2014. PMID: 24433812

9

Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).

Sonpavde G, Wang CG, Galsky MD, Oh WK, Armstrong AJ. Sonpavde G, et al. Among authors: galsky md. BJU Int. 2015 Jul;116(1):17-29. doi: 10.1111/bju.12867. Epub 2014 Oct 23. BJU Int. 2015. PMID: 25046451 Review.

10

Biomarkers for bladder cancer management: present and future.

Ye F, Wang L, Castillo-Martin M, McBride R, Galsky MD, Zhu J, Boffetta P, Zhang DY, Cordon-Cardo C. Ye F, et al. Among authors: galsky md. Am J Clin Exp Urol. 2014 Apr 5;2(1):1-14. eCollection 2014. Am J Clin Exp Urol. 2014. PMID: 25374904 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

424 results

Search Page

Filters